- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04177368
Nutritional Assessment of Children With ESRD on Dialysis
Nutritional Assessment of Children With End Stage Renel Disease(ESRD) on Regular Hemodialysis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Achieving an optimal nutritional status is essential for managing paediatric chronic kidney disease, and dietary guidance is frequently provided in clinical practice to achieve a metabolic balance, which is vital for normal growth. Guidelines addressing optimal macro- and micronutrient intake for children with CKD are available, with intake of sodium, potassium, phosphorus, protein, and total calories being common targets of nutritional monitoring.
Normal nutrition can be defined as maintenance of normal growth and body composition. Although it is agreed that nutritional assessment is important in chronic renal failure, there is no single or easy definition or measure of inadequate nutritional status: measurement of nutritional parameters are complicated in CRF because of salt and water imbalances and the potential inappropriateness of using age matched controls in a population that is short and may be delayed in puberty; it has been suggested that it is more appropriate, therefore, to express measures relative to height age and/or pubertal stage.
Malnutrition is common in hem dialysis patients and is a powerful predictor of morbidity and mortality. Although much progress has been made in recent years in identifying the causes and pathogenesis of malnutrition in hemodialysis patients, as well as recognizing the link between malnutrition and morbidity and mortality, no consensus has been reached concerning its management. Along with such conventional interventions as nutritional counseling, oral nutritional supplements, and dialectic parental nutrition, novel preventive and therapeutic strategies have been tested, such as appetite stimulants, growth hormone, androgenic anabolic steroids, and anti-inflammatory drugs, with contradictory and non conclusive results. Malnutrition still remains a great challenge for nephrologists in the third millennium.
Growth failure is almost inextricably linked with chronic kidney disease and end-stage renal disease.Growth failure in CKD has been associated with both morbidly and mortality .Growth failure in the setting of kidney disease is multi factorial and is related to poor nutritional status as well as co morbidities ,such as anemia, bone and mineral disorders, and alterations in hormonal responses, as well as to aspects of treatment such as steroid exposure. Initial reports of renal dwarfism date back to the turn of the twentieth century. Despite advances in conservative treatment and renal replacement therapies, 30-60% of patients with ESRD are short at adulthood.
Hypoalbuminemia is the most powerful predictor of mortality in end-stage renal disease. Since protein-calorie malnutrition can decrease albumin synthesis it is assumed that hypoalbu minemia results principally from malnutrition in these patients, but albumin synthesis may also be decreased as part of the acute-phase response, and hypoalbuminemia can also result from redistribution of albumin pools or from albumin losses.Serum albumin has been identified as a surrogate marker for nutritional status and morbidity / mortality in patients with end-stage renal failure. Although serum albumin may be a reflection of nutrition, low levels may be due to haemodilution, nephrotic syndrome or chronic infection / inflammation.
The most commonly used assessment of nutrition is height and weight, along with head circumference in younger children, plotted on percentile charts. Another way of expressing the relative weight and height is the body mass index, which is important because extremes are associated with increased morbidity and mortality. Skin fold thickness is a measure of subcutaneous fat and mid-arm circumference is a reflection of muscle mass and may therefore be more useful in determining body composition than the calculation of BMI alone.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age : 5-15 Years
- Sex : Male & Female
- Diagnosed as ESRD and on regular hemodialysis.
- Estimated glomerular filtration rate (eGFR): greater than or equal to 5 mL/min and less than or equal to 15 mL/min.
- Clinically stable.
Exclusion Criteria:
• Infants & adults
- Not expected to initiate dialysis
- Estimated glomerular filtration rate (eGFR): greater than or equal to 15 mL/min and less than or equal to 60 mL/min.
- Clinically unstable
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
assess nutrition with regular dialysis
This study aims to assess the growth and the nutritional status in children with end-stage kidney disease on regular hemodialysis to define the degree of malnutrition , predict and quantify the risk for complications deriving from impaired nutritional status .Giving them theragran 60ml ,twice daily for 3 month.
|
history,examination and biochemical values
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
prevention of malnutrition in children on regular dialysis
Time Frame: 1 year
|
malnutrion can be preventable by good nutrition assessment
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shimaa Kamel Ahmed, Assiut University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NACWESRD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Assessment of Nutrition in ESRD
-
Philips Clinical & Medical Affairs GlobalBetsi Cadwaladr University Health BoardCompletedIn-patients Assessment of Vital SignsUnited Kingdom
-
Catabasis PharmaceuticalsCompletedAssessment of Mechanistic Blood Biomarkers in Healthy HumansUnited States
-
Sakarya UniversityEge UniversityCompletedAssessment of Oral Health Status of Patients in Pediatric Intensive Care UnitsTurkey
-
Sohag UniversityNot yet recruitingAssessment of Some Hormone Levels in Children With Dilated CardiomyopathyEgypt
-
University of BrasiliaHospital da Criança de Brasília José AlencarNot yet recruitingPalatability Assessment of 3D-printed Chewable Tablets in Children and Adolescents
-
European Foundation for the Care of Newborn InfantsNot yet recruitingSelf-Assessment | Development of a Tool to Assess the Level of Implementing the European Standards of Care for Newborn Health | Testing of the Developed Self-assessment Tool in European HospitalsGermany
-
Dominican University New YorkRecruitingHealthy Adult Subjects | Assessment of Hip Strength, Range of Motion, EMG Activation, and Landing Mechanics in Healthy SubjectsUnited States
-
Pennington Biomedical Research CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedNutrition AssessmentUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingNutrition Assessment
-
PharmanexYonsei UniversityCompleted
Clinical Trials on Theragran 60ml
-
Caribbean Health Research CouncilThe University of The West IndiesCompletedHuman Immunodeficiency Virus (HIV) | Acquired Immune Deficiency Syndrome (AIDS)Jamaica
-
UroGen Pharma Ltd.Withdrawn
-
Suzhou Kintor Pharmaceutical Inc,Suzhou Koshine Biomedica, Inc.Active, not recruiting
-
UroGen Pharma Ltd.CompletedNeoplasms | Urologic Diseases | Urinary Bladder Diseases | Bladder CancerIsrael
-
Brigham and Women's HospitalUnknown
-
Capital Medical UniversityUnknownLower Respiratory Tract InfectionsChina
-
Northumbria UniversityCompletedCognitive DeclineUnited Kingdom
-
Northumbria UniversityCompletedHypertensionUnited Kingdom
-
Ain Shams UniversityCompletedTreatment of Iron Deficiency Anemia in PregnancyEgypt
-
Memorial Sloan Kettering Cancer CenterCompletedGastric Cancer | Pancreatic CancerUnited States